Since Gorini and Katajal found that streptomycin can phenotypically suppress (cure) auxotrophic mutations in streptomycin-resistant strains of Escherichia coli, the ribosome has been implicated in genotypic suppression. However, the role of mutations in the str locus in curing and suppression has remained unclear. In particular, it is unknown whether a mutation to str-R (see ref. 2 for terminology) can lead to genotypic suppression-i.e., suppression in absence of the drug. If it could, then the str locus would be a ribosomal suppressor locus, analogous to the tsr6 locus, in which a mutation can suppress a tryptophan auxotroph.3
Since Gorini and Katajal found that streptomycin can phenotypically suppress (cure) auxotrophic mutations in streptomycin-resistant strains of Escherichia coli, the ribosome has been implicated in genotypic suppression. However, the role of mutations in the str locus in curing and suppression has remained unclear. In particular, it is unknown whether a mutation to str-R (see ref. 2 for terminology) can lead to genotypic suppression-i.e., suppression in absence of the drug. If it could, then the str locus would be a ribosomal suppressor locus, analogous to the tsr6 locus, in which a mutation can suppress a tryptophan auxotroph. 3 Here we report experiments that further elucidate the role of mutation to streptomycin resistance in phenotypic curing and genetic suppression. We propose that mutations to any level of streptomycin resistance are not only unnecessary for curing, but tend to eliminate it. Furthermore, such mutations are incapable of causing suppression in the absence of streptomycin.
Materials and Methods.-AB774 is a K12 Escherichia coli strain sensitive to streptomycin and auxotrophic for thiamine, L-proline, L-histidine, L-isoleucine, L-valine, and L-arginine; AB301 is an Hfr strain sensitive to streptomycin and auxotrophic for L-methionine; AB312 is a str-HR strain Hfr auxotrophic for thiamine L-leucine and L-threonine; it injects markers in the order str-thi-leu; AB-2297 is an Hfr auxotrophic for L-isoleucine, Ivaline, and adenine and is sensitive to streptomycin; it transfers markers in the same order as AB312. All these strains were kindly supplied by Dr. E. A. Adelberg, Yale University.
The rich medium employed contained 10 gm nutrient broth and 10 gm casamino acids per liter. When minimal media were employed, all amino acid supplements were added to a final concentration of 0.005 per cent. Streptomycin, kanamycin, and neomycin sulfates were sterilized by filtration before use.
Streptomycin-resistant and -dependent mutants were isolated from mutagenized cultures. An inoculum of 104 cells/ml was cultured with aeration in 1 per cent nutrient broth containing 1 per cent casamino acids for eight hours; 30 ,ug/ml Nmethyl-N-nitroso-N'-nitroguanidine (nitrosoguanidine; Aldrich Chemical Co.) was then added for 40 minutes. Two ml of the mutagenized cultures were transferred to a 125-ml flask containing 40 ml of prewarmed nutrient medium, and growth was continued for another 4'/2 hours to permit expression. Samples were then plated on medium containing 200 ,g/ml streptomycin, to obtain high-level-resistant and -dependent mutants, or 10 ,ug/ml streptomycin, to obtain low-level-resistant mutants.
Transduction with P, phage was carried out by the method of Hashimoto, 4 except that phage at 3 X 109 per ml were irradiated in minimal medium to 3 per cent survival with a General Electric germicidal lamp just before they were mixed with the bacteria, in order to increase the efficiency of transduction.5
Crosses were performed by mixing the Hfr and F-cells, each at 2 X 107 cells/ml, in nutrient broth and incubating the mixed culture with very gentle agitation at 370 for two hours. Samples were then plated for recombinants on appropriate media.
Curability of strains was tested by replication of colonies from rich-medium to minimal-medium plates lacking the required growth factor (control), or to the same plates containing streptomycin, neomycin, or kanamycin. Two ,ug/ml of drug was used when str-S strains were tested; with str-R strains 10 and 100 ,gg/ml of streptomycin were used (str-R strains remain sensitive to neomycin and kanamycin).
Results.-Strain AB774 carries a mutation (arg3) that renders it auxotrophic for L-arginine. This mutation is phenotypically curable by streptomycin; the strain will grow in liquid cultures without L-arginine in the presence of 2 VOL. 58, 1967 In apparent contrast to these findings, Anderson, Gorini, and Breckenridge6 found that as many as 18 per cent of the str-HR derivatives of another curable arginine auxotroph, B40, retained curability. The genetic constitution of the original sensitive strain in their study might have been different from ours, and may have included a modifying mutation (see below). Alternatively, at least some of the curable str-HR derivatives reported6 might be, like the ones we have analyzed, double mutations that arose during isolation. The possibility that modifying mutations can arise in a strain like B40 is not entirely unlikely, for it itself is leaky,7 and contains an arginine pathway repressed by an unknown factor,6 so that growth of a curable strain requires an additional selection to obtain a derepressed derivative.
Loss of the capacity of other aminoglycoside antibiotics to cure: If mutations to str-HR indeed restrict the general capacity of ribosomes to participate in miscoding and the resultant phenotypic suppression (curing), then curing by other agents should also be impaired. This prediction has been confirmed. For example, the three strains mentioned above, AB774, N665, and N666, are curable by streptomycin, kanamycin, or neomycin. However, among str-HR derivatives prepared from them, very few could be cured by any of the drugs (Table 1) . Curability was lost even though mutations to streptomycin resistance conferred no increased resistance to kanamycin or neomycin.
Ways of obtaining curable str-HR strains: While str-Hr strains nearly always lose curability, curable variants have been obtained in four ways:
(1) From str-S strains: Rare str-HR derivatives do arise that are still curable (Table 1) , although the ones we have analyzed thus far have proven to be double mutants (see above). Such str-HR strains were also obtained by plating nitrosoguanidine-mutagenized cells of the str-S strain AB774 on minimal medium lacking arginine and containing streptomycin. Most of these curable strains were str-HD, as expected, since str-HD strains often retain curability; but 2 of 160 were str-HR. However, these two strains are once more probably double mutants, since when one was crossed to AB2297, of the 30 arg-str-HR strains isolated from among the ad+pro+ recombinants, most had lost curability.
(2) From str-HR strains: Three noncurable str-HR derivatives of AB774 (N314, N315, N316) were mutagenized, and revertants to arginine prototrophy were isolated in the presence of 10 or 100 jg/ml streptomycin. All of 450 mutants of N315 isolated on 10 jig/ml also grew without arginine in the absence of streptomycin, so that they must be revertants or suppressed strains. Similarly, of 523 isolated on 100 jig/ml of the drug, all were prototrophic in absence of the drug-i.e., none had regained curability. Very different results were obtained, however, when strains N314 and N316 were mutagenized. Of 66 derivatives of N314 that grew in the absence of arginine on plates containing 100,ug/ml streptomycin, 9 required the streptomycin for growth in absence of arginine-i.e., 9 regained curability. For N316, 3 of 11 strains selected in a similar way regained curability. Modifying mutations that can restore curability apparently depend for their isolability on the str-R mutation already in the strain. (3) From str-HD strains: Starting from a curable str-HD derivative of AB774 (N526) we isolated curable str-HR strains by two different techniques. In one method, revertants to growth without streptomycin were obtained after treatment with nitrosoguanidine; 7 of 56 still retained curability and were resistant to 100 ,.g/ml streptomycin (though, like most revertants from dependent strains,4 they were not resistant to 200 Ag/ml of streptomycin, as are str-HR and str-HD strains).
In the second method, N526 cells were transduced to str-HR with P1 grown on two different str-HR mutants (N21, a derivative of AB301, and N315, a derivative of AB774). Of the transductants from N21, 1 of 76 was curable; of the transductants from N315, 3 of 68 were curable. In these cases, the str-D mutation acts to modify the ribosome so that curability is observed even in presence of the str-HR allele.
(4) From str-LR strains: As mentioned above, 104 of 465 str-LR strains tested retained curability. Some str-HR derivatives of curable str-LR mutants continued to be curable. Sample data for high-resistant derivatives of two curable str-LR strains are shown in Table 2 : as can be seen, there was considerable variation in the capacity of str-LR alleles to permit curability. In the one case analyzed, the str-HR curable strain must have contained a noncurable str-HR mutation, because noncurable str-HR transductants could be isolated when this strain was used as a donor and the recipient was the str-S strain AB774.
Even starting from noncurable str-LR strains, curable str-HR derivatives could be isolated (Table 2) , and two such derivative strains were analyzed. One strain contained two noncurable str-LR alleles; the other contained one str-LR and one str-HR allele, both noncurable. Thus, the combination of two str-R alleles can lead to curability by streptomycin, even when each separated from the other leads to loss of curability.
Genetic analysis of some curable str-HR strains: Retention of curability in str-HR derivatives of str-LR strains suggested (1) that certain str-LR alleles might be identical to modifying mutations that restore curability to str-HR strains; and (2) that these str-LR alleles might sometimes be in the str locus. These predictions have been confirmed.
Two curable str-HR strains, derivatives of AB774, were tested. High-level resistance was transduced from one curable strain (N663) back into AB774. In 2 of 70 transductants, the modifying mutation that permits retention of curability was cotransduced with str-HR, indicating linkage. The other strain (N664) was crossed to AB2297, and 53 ad+his+arg-str-HR recombinants were analyzed; of these, 42 were curable, again indicating linkage of the modifying mutation with the str locus.
The low-level-resistant allele of strain N670, which interacts to permit curability in many str-HR strains, has also been shown to be in or near the str locus, since in a cross with a str-HR male, only 4 of 200 thr+leu+ile+val+ recombinants were sensitive to streptomycin. Failure of str-R mutations to act as suppressors: A number of attempts have been made to find mutations in the str locus that give rise to suppression even in absence of the drug. All of the approaches, including the following, have failed.
(1) For three different streptomycin-sensitive auxotrophs, a double selection was applied for mutants simultaneously str-HR and revertant to prototrophy. Eight double mutants were isolated and analyzed; in all eight, str-HR and reversion were found to have been caused by two separable mutations.
(2) It seemed possible that certain mutations might be suppressible by a mutation to str-HR, but the suppression might be lost in presence of the drug. The loss of suppression in the presence of streptomycin could arise because the drug changes the pattern of miscoding. 1 8, 9 If such a phenotype exists, it should be possible to isolate mutants from a str-HR strain which are auxotrophic only in presence of streptomycin. Of the order of 100,000 derivative colonies from 6 different str-HR strains were tested after mutagenesis by nitrosoguanidine; but no mutants were found that were auxotrophic only in the presence of streptomycin.
(3) Since mutations to str-HR might involve too drastic a change in ribosomal structure to permit suppression, we looked among str-LR strains for suppression of the arg3 mutation. Among 465 str-LR colonies isolated after nitrosoguanidine mutagenesis 2 did suppress the arg3 mutation in absence of the drug. Once again, however, both strains proved to contain two separable mutations: in crosses with a str-HR male, of 22 str-LR recombinants for one strain, 15 had lost the suppression in absence of streptomycin; similarly, for the other strain, 6 out of 13 str-LR recombinants had lost the suppression.
Discussion.-A mutation to streptomycin resistance might act to block phenotypic curing either (1) by preventing binding of the drug to the ribosome, or (2) by changing the ribosomal structure so that streptomycin could still bind, but no longer produce a sufficient level of miscoding. Since streptomycin itself seems to be required to produce the curing, one might be inclined to favor the first interpretation-i.e., no binding, no curing. However, because of the following arguments, the second interpretation is more likely.
First, one molecule of added streptomycin is bound to each ribosome (70S equivalent), whether the ribosomes are isolated from str-S or str-HR cells.'0 Also, many str-HD strains lose their curability, even though streptomycin very likely can associate with their ribosomes. Thus, binding of streptomycin does not seem to be a sufficient condition for curability.
Second, even in a curable high-resistant strain, in which streptomycin can probably bind to the ribosomes, the meaningful association to produce miscoding that leads to curing appears to be restricted by the mutation to high resistance. Thus, curing in a curable str-HR strain was found to be inferior to that in the original sensitive strain." Similarly, all the curable high-resistant derivatives we have examined, even at optimal levels of drug, never achieve growth rates as fast as those in their parental str-S strain cured with 2 ,ug/ml of the drug. Also consistent with the notion that the ribosomal change in str-HR strains restricts miscoding are the observations that genotypic suppression as well as curing tend to be lost in str-HR strains. [12] [13] [14] [15] It is interesting to note that mutations curable by streptomycin are also curable by neomycin and kanamycin,16 and that the curing capacity of all three tends to be lost in str-R strains (Table 1) . However, in vitro neomycin gives a pattern of miscoding far more extensive than that of streptomycin,9 and continues to produce miscoding even in extracts of str-HR strains.8 Thus, it is possible that neomycin and streptomycin share one type of miscoding relevant to curing in vivo, but neomycin apparently can also produce miscoding in a second way.
Modifying mutations can restore curability: The configuration of the ribosome apparently required for miscoding can often be restored in a str-R strain by a second mutation. At least some of these modifying mutations are located in or near the str locus, and in some cases themselves confer low-level resistance.
str-R mutations are not suppressors: Our unsuccessful attempts to find mutations in the str locus that are themselves suppressors, as well as the detrimental effects of str-R mutations on various suppressors, lead us to believe that the locus may not be an informational suppressor' locus. This may be why no known informational suppressor in E. coli maps near the str region."7 18 However, it is still possible that a mutation in the str locus can lead to a ribosomal configuration that will suppress.3 All that can be stated is that if such a mutation can occur, it does not lead to appreciable streptomycin resistance, and is so inefficient a suppressor that it has been generally overlooked.
Curing: The view based on the studies of Gorini and co-workers' 6, 7, 17 is that ribosomes from each strain, sensitive or resistant to streptomycin, have a certain pattern of miscoding in the presence of the drug that does not overlap completely the pattern of other ribosomes. Our findings suggest instead that the maximal potential for miscoding is already present in wild-type, streptomycin-sensitive ribosomes, and that mutation to streptomycin resistance or dependence generally acts only to restrict this potential.
One case has been reported7 of a streptomycin-sensitive auxotroph, T19-32, not cured by streptomycin, which becomes curable when a particular mutation to streptomycin resistance is introduced into it. This important result demonstrates that a mutation to str-R can lead to new misreading of a particular codon; it appears to be in conflict with our suggestion that str-R mutations generally act to restrict miscoding. However, even in this case an alternative explanation is possible. Strain T19-32 was isolated by transducing a streptomycin-sensitive allele into a curable str-HR strain. If this curable str-HR strain arose, like the ones reported here, as a result of a double mutation, then strain T19-32, when transduced to streptomycin sensitivity, might have retained the modifying mutation. Alone, the modifying mutation could well abolish curability of the leu-mutation (see above), but in combination with a newly introduced str-HR mutation, the modifying mutation would again permit curing by streptomycin. If this interpretation of the strain is valid, the leu-mutation in T19-32 should be curable by streptomycin when it is introduced into an appropriate streptomycin-sensitive strain.
Even if the strain T19-32 provides a rare exception, the available data still suggest the possibility that bacterial ribosomes in general are capable of a certain flexibility in translating the genetic code, which might have a selective advantage; in strains resistant to high levels of streptomycin, the coding fidelity of protein synthesis may increase, but flexibility is lost.
Summary.-Phenotypic tests and genetic analysis were carried out on streptomycin-resistant and -dependent mutants which were isolated from three streptomycin sensitive strains of Escherichia coli, each carrying an auxotrophic mutation phenotypically suppressed (curable) by sublethal levels of streptomycin, neomycin, or kanamycin.
The results indicate that: (1) mutations to streptomycin high resistance are unnecessary for phenotypic curing and almost invariably hinder it; (2) mutations to low-level streptomycin resistance and to streptomycin dependence also tend to eliminate phenotypic curability; (3) when curability is lost for one, it is almost always lost for all three aminoglycoside antibiotics; (4) modifying mutations (often in or very near the str locus) can restore curability to resistant strains; and (5) mutations in the str locus or in any other locus that lead to streptomycin resistance are incapable of causing suppression in the absence of streptomycin. These results are consistent with the notions that the maximal spectrum of miscoding is already present in ribosomes of streptomycin-sensitive strains, and that mutations to streptomycin resistance tend to destroy some coding flexibility of the wild-type ribosome. This flexibility might offer a selective advantage, accounting for the prevalence of streptomycin-sensitive E. coli strains in nature.
